0.20%
-5.91%
-6.09%
9.58%
-17.90%
-22.64%
110.33%
AI Spotlight on PHN
Company Description
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally.The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries.Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.
The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies.Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
Market Data
| Last Price | 50.9 |
| Change Percentage | 0.20% |
| Open | 51 |
| Previous Close | 50.8 |
| Market Cap ( Millions) | 489 |
| Volume | 16383 |
| Year High | 63.5 |
| Year Low | 44.85 |
| M A 50 | 53.47 |
| M A 200 | 52.17 |
Financial Ratios
| FCF Yield | 3.97% |
| Dividend Yield | 1.67% |
| ROE | 28.91% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | -62.35% |
| Price To Book | 8.3 |
| Price Earnings Ratio | 30.06 |
| Price To FCF | 25.18 |
| Price To sales | 4.34 |
| EV / EBITDA | 16.49 |
News
- Jan -01 - Three Elite Growth Companies With Significant Insider Ownership
- Nov -28 - Insider Confidence In Top Growth Companies For November 2024
- Nov -27 - Unveiling These 3 Undiscovered Gems with Strong Potential
- Oct -28 - Top Growth Companies With Insider Ownership In October 2024
- Sep -11 - 3 Insider-Owned Growth Stocks With 39% Earnings Expansion
- Jun -27 - PHARMANUTRA S.P.A.: THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Direct
Expected Growth : 10 %
What the company do ?
Direct from Pharmanutra S.p.A. refers to a business model where Pharmanutra, an Italian company, directly supplies its products to customers, eliminating intermediaries.
Why we expect these perspectives ?
Pharmanutra S.p.A.'s 10% growth driven by increasing demand for nutraceuticals, expanding distribution channels, and strategic partnerships. Rising health awareness, aging population, and growing preference for natural remedies also contribute to growth. Additionally, investments in R&D and innovative products, such as SiderAL, support revenue expansion.
Segment n°2 -> Indirect
Expected Growth : 12 %
What the company do ?
Indirect from Pharmanutra S.p.A. is a proprietary blend of natural ingredients that supports cardiovascular health by reducing inflammation and improving blood flow.
Why we expect these perspectives ?
Pharmanutra S.p.A.'s 12% growth is driven by increasing demand for nutraceuticals, expansion into new markets, and strategic partnerships. The company's focus on R&D has led to innovative products, enhancing its competitive edge. Additionally, growing health awareness and an aging population have contributed to the rising demand for dietary supplements, further fueling growth.
Segment n°3 -> Akern
Expected Growth : 11 %
What the company do ?
Akern from Pharmanutra S.p.A. is a dietary supplement containing S-adenosylmethionine (SAMe) for joint health and liver function support.
Why we expect these perspectives ?
Akern from Pharmanutra S.p.A. growth driven by increasing demand for natural ingredients, expanding distribution channels, and strategic partnerships. Strong R&D investments in innovative products, such as SuPlextm, and growing online presence contribute to 11% growth.
Pharmanutra S.P.A. Products
| Product Range | What is it ? |
|---|---|
| Selenium-Se | A dietary supplement containing selenium, an essential mineral that acts as an antioxidant in the body, protecting cells from damage caused by free radicals. |
| Myo-Inositol | A dietary supplement containing myo-inositol, a naturally occurring molecule involved in insulin signaling and glucose metabolism. |
| Melatonin | A dietary supplement containing melatonin, a hormone that regulates sleep-wake cycles. |
| Omega-3 | A dietary supplement containing omega-3 fatty acids, essential for heart health and brain function. |
| Probiotics | A dietary supplement containing live microorganisms that promote gut health and immune system function. |
| Coenzyme Q10 (CoQ10) | A dietary supplement containing CoQ10, an antioxidant that generates energy in cells. |
Pharmanutra S.p.A.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Pharmanutra S.p.A. is medium due to the presence of alternative products in the market, but the company's strong brand reputation and customer loyalty mitigate this threat.
Bargaining Power Of Customers
The bargaining power of customers is low for Pharmanutra S.p.A. due to the company's strong distribution network and customer relationships, which reduce the customers' ability to negotiate prices.
Bargaining Power Of Suppliers
The bargaining power of suppliers is medium for Pharmanutra S.p.A. due to the presence of multiple suppliers in the market, but the company's large scale of operations and strong relationships with suppliers mitigate this threat.
Threat Of New Entrants
The threat of new entrants is low for Pharmanutra S.p.A. due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and high capital requirements.
Intensity Of Rivalry
The intensity of rivalry is high for Pharmanutra S.p.A. due to the presence of several established players in the market, leading to intense competition and pricing pressure.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 32.98% |
| Debt Cost | 5.11% |
| Equity Weight | 67.02% |
| Equity Cost | 5.38% |
| WACC | 5.29% |
| Leverage | 49.21% |
Pharmanutra S.p.A. : Quality Control
Pharmanutra S.p.A. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PSG.DE | PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream … |
| INCR | InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis … |
| PPGN.SW | PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, … |
| BMK.L | Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe … |
| RJF.MC | Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Reig Jofre
A-Score
1-Year Total Return ->
🥈
PharmaSGP Holding
A-Score
1-Year Total Return ->
🥉
Pharmanutra
A-Score
1-Year Total Return ->
4
PolyPeptide
A-Score
1-Year Total Return ->
5
Benchmark
A-Score
1-Year Total Return ->
6
